You are here: Industry Insights > trichomoniasis

News List

Lupin gets USFDA approval of sNDA for SOLOSEC (secnidazole) to treat trichomoniasis expresspharma
July 02, 2021
SOLOSEC demonstrated a 92.2 per cent clinically and statistically significant cure rate for patients with trichomoniasis based on a landmark Phase 3 clinical trial.
Lupin announces FDA filing acceptance of sNDA for Solosec to treat trichomoniasis pharmaceutical-business-review
November 18, 2020
Lupin Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted their supplemental New Drug Application (sNDA) for Solosec® (secnidazole) for the treatment of trichomoniasis in adults and adolescents.
Lupin presents Phase 3 data for Solosec in female patients with trichomoniasis expresspharma
August 17, 2020
The company plans to submit a supplemental New Drug Application for Solosec to the FDA for the treatment of trichomoniasis later this year.
Lupin announces results of Phase 3 study of Single-Dose Solosec for treatment of trichomoniasis expresspharma
May 05, 2020
Primary endpoint successfully achieved in Phase 3 clinical trial of 147 patients.